FYR’s technology reveals what DNA alone can’t – decoding RNA and protein signals in blood to power better biomarkers, smarter trials, and improved outcomes.
FYR is pushing the limits of precision medicine by tapping into the power of Proteins and RNA through the profiling of Extracellular Vesicles (EVs) in the blood. Using AI-enabled multi–omic insights, FYR’s EV-Omics (EVO) platform unravels the complexity of disease mechanisms – taking a simple blood draw and creating a detailed molecular snapshot of the disease. By precisely understanding a patient’s disease, EVO is transforming personalized patient care through the dynamic observation of disease, from screening through therapy selection and monitoring.
Our CapabilitiesExtracellular vesicles (EVs) from diseased cells carry valuable Protein and RNA information that reflect the biology of disease. The challenge – these EVs represent a tiny fraction of the total EV population present in the blood. FYR’s proprietary SPARCs technology solves this signal-to-noise problem through the enrichment of disease-associated EVs, revealing a clearer molecular signal that unlocks the true potential of Protein and RNA in the blood.
Our TechnologyWhether you’re advancing a targeted therapy, designing a biomarker-driven trial, or building a precision diagnostic, FYR is your strategic partner. We deliver robust RNA and protein insights from blood using AI-powered EV-omics—supporting your goals from discovery through clinical validation. Our collaborative approach enables tailored study design, custom data outputs, and flexible engagement models to accelerate innovation across diagnostics, drug development, and precision medicine.
Partner with FYR